Welcome to our dedicated page for Entheon Biomedic news (Ticker: ENTBF), a resource for investors and traders seeking the latest updates and insights on Entheon Biomedic stock.
Entheon Biomedical Corp. reports corporate and biomedical developments involving governance changes, incentive stock options, material agreements, shareholder voting matters, capital-structure disclosures, and clinical or regulatory updates. Company news has included board composition changes, option grants under its shareholder-approved incentive stock option plan, and updates tied to its biomedical and genetic-testing references, including HaluGen's Psychedelics Genetic Test Kit and Lobo's Cannabis Genetic Test Kit.
Entheon (OTCQB: ENTBF) ended its business combination agreement with Nutravisor, so the planned reverse takeover, share consolidation, and name change will not proceed. Nutravisor will pay Entheon CAD $175,000 in cash and issue additional shares valued at CAD $175,000. Entheon shares remain halted.
Entheon (OTCQB: ENTBF) entered a definitive business combination agreement with Nutravisor dated January 19, 2026, to effect a three-cornered amalgamation and reverse takeover, after which Entheon will adopt Nutravisor’s business and change its name to STRYK Brands Inc.
Key terms: Nutravisor valued at $40,000,000; expected Nutravisor financings of $4.0M–$10.0M; Entheon consolidation ~6.93:1; issuance of ~53,333,333 post-consolidation shares to Nutravisor shareholders; exchange ratio 4.2395; voluntary lock-up releasing 25% every six months; finder’s fee $500,000. Closing remains subject to approvals and conditions.
Entheon (OTCQB: ENTBF) entered a binding Letter of Intent dated December 18, 2025 to acquire Nutravisor by share exchange, creating a Resulting Issuer led by Nutravisor management.
Terms include issuance of 53,333,333 Entheon shares at $0.75 each (approx. $40,000,000 post-consolidation), a required ~6.93:1 share consolidation, a $500,000 finder’s fee, a potential concurrent private placement up to $5,000,000, and a mutual break fee of $40,000. Closing is targeted by March 30, 2026, subject to due diligence, CSE approvals, listing, and other customary conditions; trading in Entheon shares was halted December 22, 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) has announced a change in its Board of Directors. Harrison Newlands has been appointed to the board effective April 3, 2025, while Andrew Hegle has resigned.
Newlands brings nearly a decade of experience in start-ups and capital markets. His notable achievements include co-founding Fire & Flower, a Canadian retail cannabis company, where he served as Director of Business Development. He also co-founded Hoshi International, a medicinal cannabis producer in Portugal, and Hypercharge Networks, Canada's first publicly traded EV charging company.
His career began as a Research Associate at MacNicol and Associates on Bay Street. He has also served as a strategic advisor for Taiga Motors, was formerly a partner at Rockbank Capital, and currently serves as a managing partner at North King Capital, where he advises public and private companies.
Entheon Biomedical Corp (OTCQB: ENTBF) has announced the issuance of stock options to company directors. The granted options allow for the purchase of up to 40,000 common shares at an exercise price of $0.145 per share. These options will remain exercisable for a two-year period from the grant date. The options are governed under the company's incentive stock option plan, which was previously approved by shareholders at the annual general meeting on December 16, 2024.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) has announced a binding letter of intent to acquire Mentis AI, a private R&D company focused on AI technologies for mental health and loneliness solutions. The acquisition will provide Entheon with AI companions and coaching tools to enhance their existing HaluGen's Psychedelics and Lobo's Cannabis Genetic Test Kit services.
The transaction will be structured as a share exchange, with Mentis AI shareholders receiving 12.84296 Entheon shares for each Mentis AI share, totaling approximately 11 million Entheon shares. Post-transaction, Mentis AI shareholders will own about 44.25% of Entheon's outstanding shares. The deal must be completed by February 28, 2025, subject to due diligence, definitive agreement execution, and regulatory approvals.